entete

SĂ©bastien Bonnet PhD; FAHA

Full Professor, Faculty of medicine, Laval University
Director of the Canadian research Chair in translational research in pulmonary vascular diseases

Principal investigator
Pulmonary Hypertension Research Group
Centre de recherche de l’Institut universitaire de cardiologie et pneumologie de Québec (CRIUCPQ)
2725, chemin Sainte-Foy, Québec (Québec), Canada, G1V 4G5

After having completed a doctorate degree in vascular physiopathology in France and a post-doctorate degree in vascular biology in Alberta, Dr. Bonnet settled in QuĂ©bec city, as an associate professor at UniversitĂ© Laval and a researcher at the Research Centre of the IUCPQ where he continues his research in the cardiovascular field. Professor Bonnet was named Fellow of American Heart Association and Director of the Canadian Research Chair in vascular pathology. This title, considered as one of the greatest honors in the scientific community, is allotted to researchers who showed leadership, creativity and exceptional competence in the advancement of fundamental and clinical research in the cardiovascular field. The accomplishments of Professor Bonnet led to the discovery of mechanisms causing pulmonary arterial hypertension, a fatal disease which strikes mainly young adults. His team also discovered two substances likely to treat this disease effectively. Drs Bonnet and Provencher are the founders and directors of the pulmonary hypertension research group.

Interests:
Pulmonary arterial hypertension (PAH); chronic obstructive pulmonary disease (COPD); coronary disease.

Work description:
The group of Dr. Bonnet uses a multidisciplinary and translational approach (from genes to population) in order to study the molecular and cellular mechanisms involved in the development of the process of vascular and bronchial remodeling. This work allows the identification of new biomarkers, thus improving the identification and clinical management of individuals afflicted by PAH. His research also identified new therapeutic targets such as Pim-1, miR-204 or PARP-1 in PAH. In addition, numerous works carried out in the laboratory of Dr. Bonnet aim at evaluating the impact of these targets in the COPD and the coronary diseases which have several similarities with PAH. The recent association of Drs Bonnet and Provencher creating the pulmonary hypertension research group offers new prospects of research in PAH. Indeed, the association of the fundamental research of Dr. Bonnet to the clinical research of Dr. Provencher allows research projects initiated in the laboratory to reach the patient's bedside which will accelerate, without any doubt, the discovery of new therapies.

Awards:

  1. 2019: Yves Morin Price, awarded to highlight the quality of its supervision of graduate students for residents and the transmission of his passion for research, Faculty of Medicine, Laval University
  2. 2019: Recognition award, scientific chair of Pulmonary Vascular Research Institute annual congress
  3. 2018: Chair elect program committee of the American Thoracic Society (2018-2020)
  4. 2017: Chair SCILL committee of the American Heart Association (2017-2019)
  5. 2017: Pulmonary Vascular Research Institute North America representative
  6. 2017: Pulmonary Vascular Research Institute Research award
  7. 2015 European Respiratory Society Research Award on Pulmonary Hypertension
  8. 2014: Prix Louise Rousselle-Trottier awarded by Fondation des maladies du coeur et de l'AVC-QuĂ©bec for his study entitled " Role for DNA damage signalling in Pulmonary Hypertension". This award of excellence is given to the researcher who has attained the highest rating evaluation for a research project on hypertension.
  9. 2013: "Jonathan Ballon" Award from the Heart and Stroke Foundation - Québec, for the highest rated scientific research project: "Role of miRNAs in pulmonary hypertension"
  10. 2012: Nominated for the Springer Junior Investigator Award of the North Amarican Vascular Biology Organization (NAVBO)
  11. 2011: Honored and distinguished member of pulmonary hypertension association
  12. 2011: American Heart Association best abstract award
  13. 2011: Nominated as fellow of the American Heart Association
  14. 2011: SQHA young investigator award
  15. 2010: Best Canadian Researcher of the month of December by CHR
  16. 2010: Hypertension Canada young investigator award
  17. 2010: Canadian Cardiovascular Society young investigator award
  18. 2009: The Cardiovascular Health Network (CHN) - Pfizer Canada Grant for the Future award
  19. 2009: American Heart Association best abstract award
  20. 2008: Heart and Stroke Foundation of Canada New Investigator Salary Award
  21. 2006: Paul Mann Award for Translational Research
  22. 2005: Fraser Mustard Award from CIHR
  23. 2004: American Heart Association Cournand & Comoroe Young Investigator Award

Grants:

  • CIHR: Replication stress and pulmonary hypertension: Role for checkpoint kinase 1 (2018-2023)
  • HSFC: Role for FOXM1 in DNA damage response and cell survival in pulmonary hypertension (2014-2017)(2017-2020)
  • CRC: Translational research in pulmonary vascular diseases (2015-2020)
  • CIHR : Role for miRNA in pulmonary hypertension (2012-2017)
  • CRC : Vascular remodeling diseases (2010-2015)
  • HSFC : miR-204 in pulmonary hypertension (2011-2014)
  • CIHR : Experimental therapies for vasculare remodeling diseases (2008-2013)

Publications:
Click here to see Dr Bonnet's publications

© 2012 Université Laval. Tous droits réservés